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ORIGINAL ARTICLE

Retargeted adenoviruses for radiation-guided gene delivery
SA Kaliberov1,2, LN Kaliberova1,2, H Yan1,2, V Kapoor1 and DE Hallahan1,2,3
The combination of radiation with radiosensitizing gene delivery or oncolytic viruses promises to provide an advantage that could
improve the therapeutic results for glioblastoma. X-rays can induce signiﬁcant molecular changes in cancer cells. We isolated the
GIRLRG peptide that binds to radiation-inducible 78 kDa glucose-regulated protein (GRP78), which is overexpressed on the plasma
membranes of irradiated cancer cells and tumor-associated microvascular endothelial cells. The goal of our study was to improve
tumor-speciﬁc adenovirus-mediated gene delivery by selectively targeting the adenovirus binding to this radiation-inducible
protein. We employed an adenoviral ﬁber replacement approach to conduct a study of the targeting utility of GRP78-binding
peptide. We have developed ﬁber-modiﬁed adenoviruses encoding the GRP78-binding peptide inserted into the ﬁber-ﬁbritin. We
have evaluated the reporter gene expression of ﬁber-modiﬁed adenoviruses in vitro using a panel of glioma cells and a human
D54MG tumor xenograft model. The obtained results demonstrated that employment of the GRP78-binding peptide resulted in
increased gene expression in irradiated tumors following infection with ﬁber-modiﬁed adenoviruses, compared with untreated
tumor cells. These studies demonstrate the feasibility of adenoviral retargeting using the GRP78-binding peptide that selectively
recognizes tumor cells responding to radiation treatment.
Cancer Gene Therapy (2016) 23, 303–314; doi:10.1038/cgt.2016.32; published online 5 August 2016

INTRODUCTION
Malignant brain tumors pose an unprecedented challenge to
developing novel, safe and effective therapies that can be
integrated into the traditional therapeutic tripod of surgery,
chemotherapy and radiotherapy (XRT).1 Glioblastoma multiforme
is the most common and highly lethal primary neoplasm of the
central nervous system. Unusual resistance of glioblastoma
multiforme to radiation and chemotherapy, their highly invasive
nature and their remarkable heterogeneity that reﬂects the
genomic instability of these tumor cells contribute substantially
to the sad fact that patient median survival has not changed
appreciably in the last few decades despite highly aggressive
therapeutic approaches.2,3
Radiation treatment is a well-established modality for cancer
therapy. Approximately half of the patients with central nervous
system cancer worldwide are treated with XRT in combination
with chemotherapy or surgery. Radiation therapy is, in general,
localized and noninvasive and does not produce systemic toxicity
after treatment in comparison with chemotherapy. Although in
recent years signiﬁcant progress in XRT methods has been
achieved, development of resistance to irradiation remains a
major problem for successful disease control. Intratumoral delivery
of therapeutic genes has the potential to become a powerful
alternative method of drug delivery. Over the last decade,
extensive progress in XRT and gene therapy combinatorial
approaches has been achieved to overcome the resistance of
tumor cells to irradiation. These efforts for development of cancer
gene therapy agents in combination with radiation include the
use of transductional and transcriptional approaches for targeting
of adenovirus (Ad) vectors. Transcriptional control of therapeutic
gene expression using promoters that are responsive to ionizing

radiation provides an attractive approach for a combination of
gene therapy and XRT. It has been shown that XRT can modulate
the expression of a large number of cellular genes involved in the
early response of tumor cells to ionizing radiation-mediated
damage. This includes genes involved in cell cycle checkpoints,
cellular stress, DNA repair and apoptosis.4
The main factor currently limiting the clinical potential of gene
therapy is the poor level of in situ tumor cell transduction
achievable by existing gene transfer approaches.5 Nevertheless,
Ad-based vectors are particularly attractive because of a wellcharacterized mechanism of cellular entry and a propensity to
infect a wide variety of cell types efﬁciently within the central
nervous system.6–8 Ad vectors have shown utility in a number of
animal models of glioma and have been investigated in several
clinical trials in adult patients with malignant glioblastomas.9,10
As all these studies employ direct intratumoral or intracavitary
injection, expression of receptors for Ad binding on these tumors
will likely determine the overall success of these and future Ad
cancer gene therapy trials. Important advances in the combination
of irradiation and gene therapy over the last decade are a result of
improved understanding of the molecular mechanisms that
mediate cancer progression and resistance to XRT.
Data from experimental and clinical studies indicate that
ionizing radiation produces DNA damage and activates multiple
intracellular signaling pathways. New antigens are thereby overexpressed and exposed on the cell membrane following XRT.
Phage display technology was exploited to identify peptides that
bind selectively to these XRT-induced neoantigens. Phage
biopanning identiﬁed peptides targeting the glucose-regulated
protein 78 (GRP78).11 Several studies have revealed the upregulation of the GRP78 expression associated with therapy resistance of
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tumor cells.12 Moreover, GRP78/BiP relocates to the cell membrane in malignant but not in benign cells.13
In this study, we have explored the utility of novel peptides that
speciﬁcally bind to XRT-induced neoantigens to achieve targeted
Ad-mediated gene transfer. Incorporation of the GRP78-binding
peptides into the ﬁber protein of the viral capsid was used to
modify tropism for Ad targeting. The results demonstrated that
employment of this modiﬁed ﬁber increased Ad-mediated gene
transfer in irradiated glioma cells. This ﬁnding provides a novel
approach for Ad gene delivery targeting to sites treated with XRT.
MATERIALS AND METHODS
Cells and reagents
293F28 cells expressing wild-type Ad5 ﬁber protein have been described
previously.14 Human glioma cell lines D54MG and U251MG (originally
obtained from Dr D Bigner, Duke University, Durham, NC), human
glioblastoma U87MG cells (HTB-14, American Type Culture Collection,
Manassas, VA, USA) and human embryonic kidney HEK293 (Microbix
Biosystems, Toronto, ON, Canada) cells were cultured in DMEM/F12
(Mediatech, Herndon, VA, USA) containing 10% fetal bovine serum
(Summit Biotechnology, Fort Collins, CO, USA). All cells were tested for
mycoplasma (MycoAlert Mycoplasma Detection Kit, Lonza, Rockland, ME,
USA) and cultured in a humidiﬁed atmosphere with 5% CO2 at 37 °C. The
recombinant enzymes were purchased from New England Biolabs (Ipswich,
MA, USA).

αVβ3/αVβ5 integrin expression, cells were stained with anti-integrin
αVβ3 antibody, clone LM609, and anti-integrin αVβ5 antibody, clone
P1F6 (MAB1976 and MAB1961, respectively, Millipore, Billerica, MA, USA),
and an anti-mouse AlexaFluor 488-labeled goat IgG (R37120, Molecular
Probes, Eugene, OR, USA). In addition, cells were evaluated for hCAR
expression using anti-CAR antibody (RmcB, 05-644, Millipore) and an antimouse AlexaFluor 488-labeled goat IgG (R37120, Molecular Probes). Mouse
IgG1 negative control, clone Ci4 (MABC002, Millipore), was used as isotype
control. Cells were incubated with Abs for 1 h at 4 °C. Following incubation
with secondary Abs, the cells were collected, washed three times in FACS
buffer, and ~ 1 × 104 cells were illuminated at 488 nm and ﬂuorescence
was detected in the ﬂuorescein isothiocyanate (525/20 nm) channel using
MACSQuant ﬂow cytometer (Miltenyi Biotec, San Diego, CA, USA). Data
were analyzed using FlowJo software (Tree Star, Ashland, OR, USA).
D54MG cells were irradiated with either a single dose of 6 Gy or
with three fractions of 3 Gy. Cells were harvested at different time points
after irradiation and stained for evaluation of the cell surface expression of
GRP78. Brieﬂy, 1 × 105 cells were incubated with anti-GRP78 rabbit
monoclonal antibody or isotype control (ab108614 and ab199376,
respectively, Abcam, Cambridge, MA, USA) for 1 h on ice. After washing
with PBS, cells were incubated with Alexa Flour 488-conjugated anti-rabbit
antibody (ab150077, Abcam) for 1 h on ice. Cells were washed with PBS
and subjected to FACS analysis as described above. Propidium iodide
(5 μg ml-1) was added for the exclusion of dead cells just before the
acquisition. Overlay histograms were prepared using FlowJo software
(Tree Star).

Immunocytochemistry

The levels of GRP78 messenger RNA were determined by reverse
transcriptase (RT-PCR). Total RNA was extracted using the RNeasy Mini
Kit (Qiagen, Valencia, CA, USA) and quantiﬁed spectrophotometrically
using an MBA2000 spectrophotometer (Perkin Elmer, Wellesley, MA, USA).
complimentary DNA (cDNA) was synthesized using random hexamer
primers and an Omniscript RT kit (Qiagen). The ﬁrst-strand cDNA was used
as the template for PCR. For ampliﬁcation of cDNA encoding GRP78,
GRP78f sense and GRP78r antisense primers were used (Table 1). Human
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA was used as
an internal standard for template loading of PCR by using the GAPDH
forward and GAPDH reverse primers (Table 1). PCR was performed under
the following conditions: 30 cycles at 95 °C for 45 s, at 55 °C for 45 s and at
72 °C for 1 min. PCR products were analyzed by 0.6% agarose electrophoresis followed by ethidium bromide staining. The relative abundance of
each PCR product was determined by semiquantitative analysis of digital
photographs of gels using Labworks 4.6 software (UVP Products, Upland,
CA, USA). The integral optical density values of GRP78 and GAPDH were
measured. The ratio of the integral optical density of GRP78 to GAPDH was
used to express the relative level of GRP78 mRNA.

Human glioma D54MG cells were allowed to grow to reach 75%
conﬂuency and then irradiated three times at 3 Gy over 24 h. The cells
were washed one time with warmed PBS and then detached using cold
PBS. The cells were counted and mounted on superfrost/plus microscope
slides (Fisher Scientiﬁc, Waltham, MA, USA). The slides were dried in air and
then ﬁxed with 4% paraformaldehyde for 10 min. For immunocytochemistry assay, air-dried smears were rehydrated in PBS, endogenous
horseradish peroxidase (HRP) activity was quenched, blocked with 5%
bovine serum albumin (BSA) plus 5% normal goat serum, and incubated
with anti-GRP78 monoclonal antibody and isotype control (ab108615 and
ab172730, respectively, Abcam) for 90 min in a humid chamber. The slides
were washed three times with PBS, and smears were incubated for 90 min
with a goat anti-mouse IgG Fc-HRP-conjugated secondary antibody (115036-068, Jackson ImmunoResearch, West Grove, PA, USA) diluted in PBS
with 0.05% Tween 20. The slides were washed with PBS and a 3,3′diaminobenzidine tetrahydrochloride substrate was added on individual
smears for immunocytochemistry staining using peroxidase-based detection. The reaction was stopped and hematoxylin counter staining was
performed. Finally, the slides were dehydrated by passing gradient
ethanol, following by xylene, and then mounted by coverslips with
permount gel (Fisher Scientiﬁc).

FACS analysis

Adenoviral vectors

To determine the levels of hCAR and αVβ3/αVβ5 integrin expression, cells
were seeded at 5 × 105 cells per well in 6-well tissue culture plates and
allowed to grow overnight. The next day, the wells were washed with
phosphate-buffered saline (PBS), and cells were collected and subjected
to ﬂuorescence-activated cell sorter (FACS) analysis. For evaluation of

Replication-incompetent E1-deleted Ad5 vectors were created using a twoplasmid rescue method. The chimeric ﬁber-ﬁbritin protein contained the
knobless Ad5 ﬁber tail region fused to the trimerizing foldon domain of the
bacteriophage T4 ﬁbritin, followed by peptide linker connecting to the
binding peptide open reading frame as described previously.15 To

RNA preparation and RT-PCR

Table 1.

PCR primers used for generation and evaluation of ﬁber-modiﬁed Ads

Name

Sequence 5′ → 3′

BamH1-GRP78-BP
GRP78-BP-Swa1
F+100 (32945-32924)
F-100 (30948-30969)
GRP78f
GRP78r
GAPDH forward
GAPDH reverse

5′-cataggatccggcggtggcggtaaaaagaaaggtggcggtggcattcgcct-3′
5′-tgccatttaaattcagccgcgcaggcgaatgccaccgccacctttct-3′
5′-GAGGTGGCAGGTTGAATACTAG-3′
5′-CCTCCTGGCTGCAAACTTTCTC-3′
5′-GATAATCAACCAACTGTTAC-3′
5′-GTATCCTCTTCACCAGTTGG-3′
5′-TCCCATCACCATCTTCCA-3′
5′-CATCACGCCACAGTTTCC-3′

Abbreviations: Ad, adenovirus; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GRP78, glucose-regulated protein 78.
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generate a PCR product encoding a fragment of the binding peptide open
reading frames-speciﬁc primers were used (Table 1). The PCR product was
cloned into a plasmid pKan566FF using BamHI and SwaI sites to generate
pKan566FF-GRP78-BP. Insertion sequences were conﬁrmed by using
restriction enzyme mapping and partial sequence analysis. The shuttle
plasmids were digested using EcoRI and SalI enzymes and integrated into
the Ad5 genome by homologous recombination in the Escherichia coli
strain BJ5183 with pVK700 or pVK900 plasmid comprising the human
cytomegalovirus major immediate-early enhancer/promoter element
coupled to the ﬁreﬂy luciferase (Luc) or enhanced green ﬂuorescent
protein (eGFP) genes, respectively, followed by the bovine growth
hormone polyadenylation signal. The recombinant viral genomes with
binding peptide-ﬁber-ﬁbritin fusions were linearized with PacI and then
transfected into 293F28 cells stably expressing the native Ad5 ﬁber14 using
SuperFect Transfection Reagent (Qiagen, Chatsworth, CA). Following an
additional round of ampliﬁcation on 293F28 cells, the viruses were
ampliﬁed in HEK293 cells and puriﬁed twice by CsCl gradient centrifugation and dialyzed against PBS with 10% glycerol as previously described.16
To verify inserted modiﬁcations of the ﬁber gene all viral genomes were
subjected to partial sequencing analysis. The concentration of physical
viral particles (vp) was determined by measuring the absorbance of the
dissociated virus at A260 nm using a conversion factor of 1.1 × 1012 vp per
absorbance unit.17 The multiplicity of infection for subsequent experiments was expressed as vp per cell.

Polymerase chain reaction
To conﬁrm the presence of chimeric ﬁber-ﬁbritin genes in the Ad
genomes, viral genomic DNA was extracted from 1 × 107 vp of puriﬁed viral
stock by using a QIAamp DNA Mini Kit (Qiagen). For detection of the
Ad ﬁber gene, F-100 sense and F+100 antisense primers were used
(Table 1). After the initial denaturation (5 min at 95 °C), ampliﬁcation was
performed with 30 cycles at 95 °C for 15 s, at 60 °C for 1 min, and at 72 °C
for 1 min, and a ﬁnal extension of 10 min at 72 °C. PCR products were
analyzed by 0.6% agarose electrophoresis with ethidium bromide staining.

Western blot assay
For evaluation of ﬁber-ﬁbritin expression the samples containing 5 × 109 vp
were preincubated in Laemmli sample buffer for 10 min at 99 °C or at 25 °C
for semi-native conditions. Proteins were separated using a 4–20%
gradient polyacrylamide Precise Protein gel (Thermo Scientiﬁc, Wilmington, DE, USA). The proteins were blotted onto polyvinylidene diﬂuoride
membrane membranes and developed with the Sigma FAST 3,3′diaminobenzidine system (Sigma-Aldrich, St Louis, MO, USA) according
to the manufacturer’s protocol. Anti-adenovirus ﬁber monoclonal antibody
(Ab-4 (clone 4D2); MS-1027, Thermo Scientiﬁc) and polyclonal goat antimouse Ig-HRP (P0447, DakoCytomation Denmark A/S, Glostrup, Denmark)
were used for Ad ﬁber protein detection.
The level of GRP78/BiP protein expression was also determined by
immunoblotting techniques. Brieﬂy, cells were collected and washed in
Tris-buffered saline (TBS, 135 mM NaCl, 2.5 mM KCl, 25 mM Tris-HCl and pH
7.5) and homogenized in ice-cold lysis buffer (50 mM Tris-HCl, 150 mM NaCl,
2 mM EDTA and 1% IGEPAL CA-630 (Sigma-Aldrich). The homogenate was
centrifuged at 14 000 × g for 5 min and the protein concentration was
determined by the Biuret method using the BCA Protein Assay Kit (Pierce,
Rockford, IL, USA). Each sample was denatured for 5 min at 99 °C in loading
buffer and separated on SDS–PAGE using a 4–20% gradient polyacrylamide Precise Protein gel (Thermo Scientiﬁc) followed by transfer to a
polyvinylidene diﬂuoride membrane (Millipore). The membrane was
blocked with 5% non-fat milk (Bio-Rad, Hercules, CA, USA) in TBS, and
expression of GRP78/BiP and β-actin in the cell homogenate was detected
using speciﬁc anti-BiP rabbit monoclonal antibody (C50B12; 3177, Cell
Signaling Technology, Boston, MA, USA) and polyclonal goat anti-rabbit IgHRP (P0447, DakoCytomation Denmark A/S) secondary antibody, and antiβ-actin mouse monoclonal antibody (AC-15; ab6276, Abcam) and
polyclonal goat anti-mouse Ig-HRP secondary antibody (P0447, DakoCytomation Denmark A/S), respectively. Signals were detected using ECL
Western Blotting Detection Reagents (GE Healthcare, Buckinghamshire,
UK). Equal loading was veriﬁed by monitoring the expression levels of
β-actin.

Gene transfer and Luc assay
Cells were seeded at 5 × 104 cells per well in 24-well tissue culture plates
and allowed to grow overnight. The next day, cells were infected with

different multiplicities of infection in triplicate. After incubation at 37 °C
for 1 h, media was removed and fresh media was added. Forty-eight hours
later the media was removed, cells were washed one time with PBS, lysed,
and Luc activity was determined using the Luciferase Assay System
(Promega, Madison, WI, USA) and Femtomaster-FB12 luminometer (Zylux
Corp., Oak Ridge, TN, USA) according to the manufacturers’ instructions.
Luc activity was normalized to the protein concentration of the cell lysate
using DC Protein Assay (Bio-Rad) according to the manufacturer’s
instructions. The results are expressed as relative light units per 5 × 104
cells, and bars represent the mean ± s.d.

Expression of recombinant Ad5 knob
The knob domain of Ad5 ﬁber protein was expressed in E. coli as described
previously.18 Soluble His-tagged Ad5 knob was puriﬁed by gravity-ﬂow
afﬁnity chromatography using a Ni-NTA resin (Qiagen). The concentration
of the puriﬁed protein was determined using DC Protein Assay (Bio-Rad)
according to the manufacturer’s instructions. The purity of the recombinant protein was monitored by western blotting using anti-His monoclonal
antibody (HIS-1, H1029, Sigma) and goat anti-mouse Ig-HRP (P0447,
DakoCytomation Denmark A/S).

Competitive inhibition assay
To block hCAR-speciﬁc transduction, D54MG cells were seeded at 1 × 105
cells per well in a 24-well tissue culture plate and incubated after 1 day
with 100 μg ml-1 of soluble Ad5 knob protein for 1 h at 4 °C before
infection with 2 × 103 vp per cell of Ad5eGFP or AdGRP78-BPeGFP.
Forty-eight hours after infection, eGFP expression was visualized using
ﬂuorescence microscopy.
To block GRP78-speciﬁc binding, cells were seeded at 1 × 105 cells per well
in a 24-well tissue culture plate. AdGRP78-BPLuc and AdFFLuc were
incubated with 200 μg ml-1 of recombinant BiP protein (ab176142, Abcam)
or BSA at 37 °C for 30 min. Cells were then washed one time with PBS and
infected with Ads at 2 × 103 vp per cell. After incubation for 1 h at 37 °C, cell
culture media was removed, cells were washed with PBS, and fresh media
was added. In addition, D54MG cells were preincubated with 50 μg ml-1 of
BiP/GRP78 rabbit monoclonal antibody (C50B12; 3177, Cell Signaling
Technology) or BSA for 1 h before infection with AdGRP78-BPLuc or
AdFFLuc. Cells were then infected with Ads at 2 × 103 vp per cell. After 48 h,
cells were washed one time with PBS and lysed. Luc activity was determined
as described above.

Animal study
For in vivo experiments, 4–6-week-old female nude athymic mice were
purchased from the Envigo (Indianapolis, IN, USA) and housed under
aseptic conditions in microisolator cages, and experiments were carried
out according to the protocols approved by the Institutional Animal Care
and Use Committee, approved by the Division of Comparative Medicine,
School of Medicine, Washington University in St Louis. To establish human
tumor xenografts 1 × 106 D54MG cells were injected subcutaneously (s.c.)
into both left and right ﬂanks of mice. Following tumor injection, mice
were returned to their sterile microisolator cages and maintained on
autoclaved lab-chow and sterile water ad libitum. Radiation therapy studies
were carried out in s.c. models in which animals were treated with Ad
vectors at the time of established tumor growth (~0.5 cm3). Imaging and
imaging analysis were performed in the Optical Radiology Laboratory,
Mallinckrodt Institute of Radiology, School of Medicine, Siteman Cancer
Center, Washington University in St Louis.

Statistical analysis
In experiments where triplicates were run to reduce measurement error,
statistical analyses were conducted on the mean triplicate value. All error
terms are expressed as the s.d. of the mean. Signiﬁcance levels for
comparison of differences between groups in the experiments were
analyzed using the Student's t- test. All reported P-values are two-sided.
The differences between groups were considered statistically signiﬁcant
when the P-value was ⩽ 0.05.
Cancer Gene Therapy (2016), 303 – 314
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RESULTS
Evaluation of GRP78 expression
The expression of GRP78 mRNA was examined using RT-PCR of
total mRNA of cells after irradiation. The GAPDH cDNA was used as
an internal standard for template loading. PCR products were
separated by electrophoresis and the relative abundance of PCR
products was semiquantiﬁed by densitometry. All tested glioma
cells demonstrated a dose-dependent increase of GRP78 gene
expression following radiation treatment in comparison with
mock-irradiated cells (Figure 1a). On the basis of the results of this
initial screening, we used D54MG cells that demonstrated the
highest levels of GRP78 expression after irradiation for subsequent
experiments.
To evaluate GRP78 protein expression following XRT, D54MG
cells were irradiated at 3 Gy, 6 Gy, three times at 3 Gy, or mock
irradiated. Twenty-four hours after the last radiation treatment cell
lysates were subjected to western blotting analysis. As shown in
Figure 1b, expression of GRP78 mRNA in D54MG cells was
associated with a dose-dependent increase in the levels of GRP78
protein expression following radiation treatment. As seen in
Figure 1c, there was a time-dependent increase in GRP78 protein
expression following intermediate dose of XRT at 6 Gy, which was
evident at 6 h, and reached a peak expression 24–48 h after
radiation treatment. Similar results were obtained with other
glioma cells (data not shown).
To investigate whether XRT can increase GRP78 expression on
the cell surface, D54MG cells were irradiated with a single dose of
6 Gy XRT, harvested at different time points after irradiation and
subjected to ﬂow cytometric assay (Figure 1d). As can be seen
from the overlay histograms, ~ 60–65% of cells were positive for
surface GRP78 expression at time points 0, 1, 6 and 18 h after
irradiation. Slight increase in the percentage of positive cells
(73.1%) was observed at 24 h. The highest level of GRP78 surface
expression was observed at 48 h after radiation treatment (90.4%).
D54MG cells were also irradiated with three fractions of 3 Gy over
a course of 24 h and harvested 24 h after the last XRT (Figure 1e).
We observed a higher induction of GRP78 surface expression
(96.6%) with fractionated XRT at an earlier time point (24 h) as
compared with the single dose of 6 Gy. Therefore, all further
experiments were performed with three fractions of 3 Gy
irradiation.
In addition, D54MG cells were irradiated three times at 3 or 0 Gy
and subjected to immunocytochemistry analysis at 24 h after the
last radiation treatment. As illustrated in Figure 1f, immunocytochemistry analysis revealed an increasing number of stained
D54MG cells (shown in brown diaminobenzidine tetrahydrochloride biding color on the cell membrane) irradiated three times
at 3 Gy in comparison with mock-irradiated cells. There was no
signal observed using normal mouse IgG and secondary antibody
controls.
Rescue and validation of Ad vectors incorporating binding
peptides
For this study, we developed a panel of recombinant replicationincompetent Ad5-based vectors expressing the ﬁreﬂy Luc or eGFP
gene under transcriptional control of the human cytomegalovirus
major immediate-early enhancer/promoter element. A simpliﬁed
schematic diagram of recombinant Ad genomes used in this study
is presented in Table 2. To develop AdGRP78-BPLuc and AdGRP78BPeGFP recombinant Ads the chimeric ﬁber-ﬁbritin protein-coding
DNA containing the entire Ad5 ﬁber shaft fused to the 12th coiledcoil (foldon) trimerizing domain of bacteriophage T4 followed by a
3x(GGGGS) peptide linker connected to a KKKGGGGIRLRG peptide.
Vectors expressing chimeric ﬁber-ﬁbritin (AdFFLuc) and wild-type
Ad5 ﬁber (Ad5Luc and Ad5eGFP) were used as isogenic controls
and as wild-type control Ad vectors, respectively.
Cancer Gene Therapy (2016), 303 – 314

PCR analysis was used to demonstrate the incorporation of
the chimeric ﬁber-ﬁbritin gene region in the Ad genome. The
PCR was performed using Ad5-speciﬁc primers, which anneal
at 100 bp upstream and downstream of the ﬁber gene, and
puriﬁed AdGRP78-BPeGFP, Ad5Luc, Ad5eGFP, AdGRP78-BPLuc
and AdFFLuc viral genome DNA as templates. As shown in
Figure 2a, the PCR analysis demonstrated the ampliﬁcation of the
corresponding ﬁber region in each of the Ads.
To demonstrate the incorporation of the targeting ﬁber-ﬁbritin
fusion proteins into the virus particle, 5 × 109 vp of boiled and
unboiled puriﬁed Ads were loaded in each lane and subjected
to SDS–PAGE followed by western blotting analysis using antiﬁber monoclonal antibody. The predicted molecular weight
of ﬁber monomers is 61.6 kDa for Ad5Luc and 52.7 kDa for
vectors encoding chimeric ﬁber-ﬁbritin proteins. As illustrated in
Figure 2b, genetic incorporation of binding peptides into ﬁberﬁbritin produced stable fusion with ﬁber-ﬁbritin molecules that
maintained the trimerization potential of ﬁber-ﬁbritin chimeric
proteins under native conditions.
For initial determination of transduction efﬁciency and speciﬁcity of ﬁber-modiﬁed Ad, human glioma D54MG, U87MG and
U251MG cells were irradiated three times at 3 Gy over 24 h and
then infected with Ad5eGFP or AdGRP78-BPeGFP recombinant
Ads. Fluorescence microscopy was performed 48 h after infection
using an Olympus IX70 inverted ﬂuorescence microscope (Tokyo,
Japan). All samples were analyzed in a blinded manner, and
images shown are representative of three wells per group with the
experiment performed three times. As shown in Figure 2c, GIRLRG
peptides fused to ﬁber-ﬁbritin provided retargeting of Admediated eGFP gene transfer of irradiated cancer cells. These
results correlated with GRP78 expression in the human glioma
cell lines.
XRT induction of neoantigens allows enhanced gene transfer in
glioma cells via ﬁber-modiﬁed Ads
To conﬁrm that ﬁber modiﬁcations resulted in Ad retargeting,
human glioma cells were irradiated three times at 3 Gy over 24 h
and infected with AdGRP78-BPLuc. AdFFLuc vector expressing
ﬁber-ﬁbritin and Ad5Luc displaying a wild-type Ad5 ﬁber was used
as an isogenic control and wild-type control Ad vector,
respectively. The level of Luc reporter gene expression was
measured 48 h after infection. The relative levels of Luc expression
in glioma cells were assessed by determining the ratio of Luc
activity in irradiated cells to that in mock-irradiated cells. For each
cell line, three independent experiments were carried out in
triplicate cultures and normalized for protein. Statistical analyses
were conducted on the mean triplicate value from each
experiment. Before XRT, the mean Luc reporter gene expression
at baseline in all cell lines was not signiﬁcantly different between
treatment groups (P40.05), and the within-treatment variances
were not signiﬁcantly different (P40.05). As shown in Figure 3a,
gene transfer efﬁciency of Ad5Luc and AdFFLuc was not
signiﬁcantly altered following irradiation of glioma cells. In
contrast, gene transfer efﬁciency of AdGRP78-BPLuc was increased
following XRT in all tested cells. The AdGRP78-BPLuc-infected
D54MG cells had greater relative Luc expression after irradiation
than did U87MG or U251MG cells (interaction P-value = 0.05).
For the D54MG cell line, there was signiﬁcantly greater Luc
expression in cells infected with AdGRP78-BPLuc following XRT,
versus mock-irradiated cells (P-value o 0.05), but no signiﬁcant
difference between those cells infected with Ad5Luc or AdFFLuc
(P-value = 0.2).
Next, we evaluated the Luc activity in D54MG cells following
XRT using different doses of radiation (Figure 3b). This doseescalation study demonstrated a dose-dependent increase in XRT/
mock ratios of Luc expression in AdGRP78-BPLuc-infected cells.
There were signiﬁcant differences across the doses of radiation for
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Figure 1. Evaluation of GRP78 expression. (a) The level of GRP78 mRNA expression was determined by RT-PCR. Human glioma cells were
irradiated at 3 Gy (3 Gy), three times at 3 Gy (3 × 3 Gy), or untreated (mock), and total RNA was extracted; the ﬁrst-strand cDNA was synthesized
using random hexamer primers and used as the template for PCR. GAPDH cDNA was used as an internal standard. Products of PCR were
analyzed by 0.6% agarose electrophoresis with ethidium bromide staining. One representative of two different experiments is shown.
(b) Evaluation of GRP78 protein expression following XRT. D54MG cells were irradiated at 3 Gy, 6 Gy, three times at 3 Gy (3 × 3 Gy) or mock
irradiated. Cells were collected 24 h after the last radiation treatment and equal volumes of cell lysates were loaded in each lane with boiling
in a sample buffer, separated on SDS–PAGE, followed by transfer to a PVDF membrane and western blotting analysis using anti-GRP78/BiP
antibody. One representative of two different experiments is shown. (c) D54MG cells were irradiated at 6 Gy or mock irradiated, collected at
different time points after radiation treatment, and equal volumes of cell lysates were loaded in each lane with boiling in a sample buffer and
separated on SDS–PAGE followed by transfer to a PVDF membrane and western blotting analysis using speciﬁc anti-GRP78/BiP antibody. The
human actin protein was used as a loading control. One representative of three different experiments is shown. (d) Evaluation of surface
expression of GRP78 using ﬂow cytometric analysis. D54MG glioma cells were irradiated with a single dose at 6 Gy and harvested at the
indicated time points after XRT. Highest surface expression of GRP78 was observed 48 h after irradiation. (e) D54MG cells were irradiated three
times at 3 Gy over 24 h and harvested at 24 h post irradiation. Overlay histograms show increased surface expression of GRP78 after
irradiation. The broken line indicates isotype control antibody and the solid line indicates anti-GRP78 antibody. (f) Evaluation of GRP78
expression on the cell surface using immunocytochemistry analysis. D54MG cells were irradiated three times at 3 Gy or 0 Gy. Examination of
DAB-stained cells showed that irradiation increased the number of GRP78-positive (brown-stained) cells compared with mock-irradiated cells.
cDNA, complimentary DNA; DAB, diaminobenzidine tetrahydrochloride; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GRP78,
glucose-regulated protein 78; PVDF, polyvinylidene diﬂuoride; RT-PCR, reverse transcriptase PCR; XRT, radiotherapy.
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Schematic diagram of the Ad vectors used in this study

Vector

Reporter
gene

Fiber protein

Target

Ad5Luc
Ad5eGFP
AdGRP78-BPeGFP
AdGRP78-BPLuc
AdFFLuc

Luc
eGFP
eGFP
Luc
Luc

Wild-type Ad5
Wild-type Ad5
KKKGGGGIRLRG
KKKGGGGIRLRG
Fiber-ﬁbritin
(no binding domain)

CAR
CAR
GRP78
GRP78
NA

Abbreviations: Ad, adenovirus; eGFP, enhanced green ﬂuorescent protein;
GFP, green ﬂuorescent protein; GRP78, glucose-regulated protein 78; Luc,
luciferase; NA, not applicable. Genomic regions relevant to our studies
are shown.

D54MG cells infected with AdGRP78-BPLuc (P-value o 0.05), but
no signiﬁcant differences between cells infected with Ad5Luc or
AdFFLuc (P-value = 0.1).
Ad transduction efﬁciency to human glioma cells is highly
variable, and gene transfer levels correlate directly with the level
of expression of the primary receptor for Ad on the cell surface.
Thus, low levels of expression of CAR in most tumor cells may be a
major limiting factor for the success of Ad5-based gene therapy.
We evaluated whether a modiﬁcation in the Ad ﬁber resulted in
the ability of ﬁber-modiﬁed Ads to achieve CAR-independent
binding and infection in vitro. As previous studies demonstrated
the ability of recombinant Ad5 knob to block binding of the
corresponding Ad5 vectors or recombinant ﬁber protein to its
receptor,18 we expressed recombinant Ad5 knob and determined
the purity of the recombinant proteins by western blotting with
anti-His monoclonal antibody (data not shown). The expression of
αvβ3/αvβ5 integrins and CAR on the surface of human cancer
cells was examined using FACS (Table 3). As shown in Figure 3c,
Cancer Gene Therapy (2016), 303 – 314

preincubation with Ad5 knob did not inhibit the AdGRP78BPeGFP-mediated eGFP expression in D54MG cells. In
contrast, Ad5eGFP infection was efﬁciently inhibited by recombinant Ad5 knob in proportion to protein concentrations (results not
shown).
To conﬁrm the speciﬁcity of AdGRP78-BPLuc infection we
evaluated GRP78/BiP-mediated inhibition of Luc gene transfer.
For this study, AdGRP78-BPLuc or AdFFLuc was preincubated with
GRP78/BiP recombinant protein for 1 h before infection of D54MG
cells. Incubation of AdGRP78-BPLuc with BSA was used as control.
In addition, D54MG cells were preincubated with BiP/GRP78
rabbit monoclonal antibody or BSA for 1 h before infection with
Ads. Forty-eight hours after infection, Luc activity was measured
(Figure 3d). Gene transfer efﬁciency of AdGRP78-BPLuc was
signiﬁcantly reduced after incubation with blocking proteins,
and only ~ 40% of Luc expression was retained following infection
with AdGRP78-BPLuc, and ~ 49% after incubation of D54MG cells
with anti-BiP/GRP78 monoclonal antibody (P-value o 0.05). Results
of a gene transfer blocking assay demonstrated inhibition of Luc
gene transfer in D54MG cells following pretreatment of ﬁbermodiﬁed Ads with blocking protein in a dose-dependent manner
(data not shown).
In vivo analysis of Ad vector targeting to XRT-induced neoantigens
Initially, we investigated whether modiﬁcations of Ad ﬁber protein
alter Ad in vivo selectivity for XRT-induced neoantigen, subsequent to Ad-mediated gene transfer. To evaluate Ad-mediated
eGFP expression in vivo, mice bearing D54MG human tumor
xenografts (n = 3) were irradiated three times at 3 Gy over 24 h
in the right ﬂank, then injected i.t. in both sites with AdGRP78BPeGFP, and eGFP expression was evaluated at different time
points after injection. As illustrated in representative optical
images (Figure 4a), eGFP expression was detected in tumors
injected with AdGRP78-BPeGFP as early as 24 h after injection and
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reached a peak at 3–7 days post injection. Results of ﬂuorescence
imaging analysis of eGFP expression in irradiated and mockirradiated xenografts on individual D54MG tumor-bearing
mice are summarized in Figure 4b. There was increasing eGFP
expression (XRT/mock ratios) following AdGRP78-BPeGFP injection
in the irradiated xenografts in comparison with mock-treated
tumors (Figure 4c). Despite high levels of eGFP expression in
D54MG tumors following XRT, immunohistochemical analysis
revealed no difference in the biodistribution of eGFP expression
in a cross-section of tumor from mice following local administration of AdGRP78-BPeGFP in comparison with Ad5eGFP injection
(data not shown).
To evaluate Ad-mediated Luc expression in vivo, mice bearing
D54MG human tumor xenografts were irradiated three times at

3 Gy over 24 h in the right ﬂank, and then were randomly divided
into groups (n = 4–5) receiving 1 × 1010 vp per tumor of AdGRP78BPLuc or Ad5Luc. Tumors were collected at 3 days after administration of AdGRP78-BPLuc or Ad5Luc, and the levels of Luc
expression were determined. Results of Luc expression assay in
irradiated and mock-irradiated D54MG tumors are summarized in
Figure 4d. To quantify the relative levels of Luc expression we
used the irradiated-to-mock-irradiated (XRT/mock) ratios of Luc
activity in tumors. Irradiated-to-mock-irradiated ratios were
calculated for each animal with the relative light units normalized
by the protein concentration of the tumor tissue lysate. As shown
in Figure 4e, the XRT-to-mock-irradiated ratio of Luc expression
was increased 18-fold for tumors injected with AdGRP78-BPLuc, in
comparison with mice injected with Ad5Luc.

(-) XRT
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1796 bp

D54MG

3x3 Gy

(-) XRT

U87MG

3x3 Gy

Trimers
(-) XRT

61.6 kDa

Monomers

U251MG

52.7 kDa
3x3 Gy

B U B U

U B

U B U B

Figure 2. Validation of genetic incorporation of GRP78-binding peptides into ﬁber-ﬁbritin and Ad targeting to XRT-induced neoantigens.
(a) Validation of genetic incorporation of binding peptides into ﬁber-ﬁbritin using PCR. Viral genomic DNA was extracted from puriﬁed viral
stock and subjected to PCR analysis. PCR products were analyzed by means of 0.6% agarose electrophoresis with ethidium bromide staining.
L, 1 kb DNA Ladder. One representative of two different experiments is shown. (b) Assessment of incorporation of ﬁber-ﬁbritin proteins with
binding peptide into Ad particles using western blotting analysis. Equal amounts (5 × 109 vp) of puriﬁed Ads were loaded into each lane with
boiling in a sample buffer (B) or without boiling (U) and separated on SDS–PAGE followed by transfer to a PVDF membrane. Fiber protein
expression was detected using anti-ﬁber monoclonal antibody. One representative of two different experiments is shown. (c) Adenoviral
vector targeting to XRT-induced neoantigens—in vitro eGFP expression. For initial determination of transduction efﬁciency and speciﬁcity of
Ad-mediated eGFP expression, human glioma cells were irradiated three times at 3 Gy over 24 h (3 × 3 Gy) or mock treated (‘-’ XRT) and then
infected with 1 × 103 vp per cell of AdGRP78-BPeGFP or Ad5eGFP recombinant Ads. Forty-eight hours after infection, cellular eGFP expression
was visualized using ﬂuorescence microscopy. One representative of three different experiments is shown. Ad, adenovirus; eGFP, enhanced
green ﬂuorescent protein; GFP, green ﬂuorescent protein; GRP78, glucose-regulated protein 78; PVDF, polyvinylidene diﬂuoride; VP, viral
particles; XRT, radiotherapy.
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Figure 3. XRT induction of neoantigens allows enhanced gene transfer into human glioma cells via ﬁber-modiﬁed Ads. (a) Evaluation of the
efﬁcacy and speciﬁcity of the XRT-induced neoantigen-targeted gene transfer. Glioma cells were irradiated three times at 3 Gy over 24 h and
infected with AdGRP78-BPLuc, AdFFLuc or Ad5Luc vector. Luc activity was detected in the lysates of infected cells at 48 h after infection. Data
are presented as the irradiated-to-mock-irradiated ratio of Luc activity, and bars represent the mean ± s.d. of three independent experiments,
each performed in three replicates (*, P o0.05; versus mock). (b) Dose-dependent targeting of adenoviral vectors to XRT-induced neoantigens.
D54MG cells were irradiated at 3 Gy, 6 Gy, three times at 3 Gy, or mock irradiated, and then infected with AdGRP78-BPLuc, AdFFLuc or Ad5Luc.
Luc activity was monitored in the cell lysates at 48 h post infection. Data are presented as the irradiated-to-mock-irradiated ratio of Luc
activity, and bars represent the mean ± s.d. of three independent experiments, each performed in three replicates (*, Po 0.05; versus mock).
(c) Validation of hCAR-independent infection. For competition blocking assay, D54MG cells were preincubated with soluble Ad5 knob protein
or BSA and infected with 2 × 103 vp per cell of Ad5eGFP or AdGRP78-BPeGFP recombinant Ads. Forty-eight hours after infection, eGFP
expression was visualized using ﬂuorescence microscopy. One representative of three different experiments is shown. (d) Validation of target
speciﬁcity for XRT-induced neoantigens targeting. AdGRP78-BPLuc and AdFFLuc were preincubated with GRP78/BiP or BSA; D54MG cells were
infected with Ads at 2 × 103 vp per cell. In addition, D54MG cells were incubated with anti-GRP78/BiP monoclonal antibody (anti-BiP mAb) or
with BSA for 1 h and infected with Ads at 2 × 103 vp per cell. Luc activity was detected in the cell lysates at 48 h post infection. Relative Luc
expression is given as a percentage of the Luc activity of BSA-treated samples. Data are presented as mean ± s.d. of three independent
experiments, each performed in three replicates (*, Po0.05 versus BSA). Ad, adenovirus; BSA, bovine serum albumin; eGFP, enhanced green
ﬂuorescent protein; GFP, green ﬂuorescent protein; GRP78, glucose-regulated protein 78; Luc, luciferase; VP, viral particles; XRT, radiotherapy.

DISCUSSION
Glioblastoma multiforme is one of the most aggressive types of
malignancies with very high mortality. The existing treatment
options consist of surgery and radiation therapy in combination
with temozolomide and have far fallen short of breakthrough
success.19–21 Malignant gliomas are known to invade the
surrounding normal brain tissue, which results in incomplete
surgical resection and high incidence of recurrence. Gliomas have
a dismal median overall survival of about 15 months.22 Thus, it is
imperative to exploit new therapeutic approaches to improve the
clinical outcome of this disease. The reason for this poor response
to radiation treatment is believed to be dependent on a subset of
Cancer Gene Therapy (2016), 303 – 314

tumor cells exhibiting XRT resistance. Thus, development of an
effective therapy for the treatment of gliomas is predicated on
efﬁciently targeting XRT-resistant tumor cells. In order to overcome XRT resistance, strategies involving a combination of radiation therapy and gene therapy have been extensively investigated. A growing body of evidence demonstrates the promise
of gene therapy in preclinical and early clinical studies.23,24 Gene
delivery techniques to the brain have been generally based on the
direct injection of the gene therapy vector into the tumor mass or
into the surgical cavity margin after tumor debulking.
XRT, as a part of standard therapy for glioma, consisted of
fractionated focal irradiation at a dose of 2 Gy per fraction for a
total dose of 60 Gy alone or in combination with chemotherapy.25
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Table 3.

Flow cytometric analysis of αvβ3 and αvβ5 integrins and CAR
surface expression
Cell line

% of positive cells (mean of ﬂuorescence intensity)a
αvβ3

U251MG
U373MG
U87MG
D54MG
HEK293

26 ± 4
86 ± 6
42 ± 4
90 ± 8
89 ± 10

(22 ± 9)
(60 ± 14)
(46 ± 7)
(66 ± 9)
(87 ± 12)

αvβ5
94 ± 6
90 ± 7
83 ± 8
91 ± 6
92 ± 7

(63 ± 10)
(55 ± 6)
(53 ± 12)
(57 ± 11)
(94 ± 20)

CAR
55 ± 7
32 ± 4
12 ± 2
37 ± 4
96 ± 8

(101 ± 11)
(37 ± 6)
(14 ± 5)
(49 ± 5)
(76 ± 6)

Abbreviation: FACS, ﬂuorescence-activated cell sorter. aHuman cancer cells
were stained with saturating amounts of monoclonal antibodies recognizing αvβ3, αvβ5 or hCAR, and expression was evaluated by FACS analysis. A
negative immunoglobulin G isotype primary mouse antibody was used as
a control. Data are the means ± s.d. of three independent experiments.

It is now well known that exposure of tumor cells to clinically
relevant doses of XRT triggers a large network of intracellular
signaling pathways that collectively produce a multilayered biological response and eventually can result in the development of
XRT resistance. Over the past decade, it has been shown that XRT
produces overexpression of GRP78/BiP11 on the cell membrane.
We have earlier evaluated GRP78 expression at various doses of
XRT at different time points after irradiation.26 We observed that
expression of GRP78 is dose and time dependent. The maximum
expression of GRP78 was observed at 72 h after XRT at 6 Gy.26
In this study, GRP78 expression was analyzed using immunocytochemistry and ﬂow cytometric assay. These two methods are
complementary in their representation of GRP78 expression on
the cell surface, with immunostaining allowing clear identiﬁcation
of cell surface expression and ﬂow cytometry allowing for
sensitive quantiﬁcation of GRP78 protein expression. These studies
have conﬁrmed higher induction of GRP78 surface expression
after fractionated XRT at an earlier time point (24 h) in comparison
with the single dose of 6 Gy.
Phage-display peptide biopanning has been successfully used
to identify GIRLRG peptides targeting XRT-inducible neoantigen
GRP78/BiP.11 GRP78/BiP is a member of the Hsp70 superfamily
of chaperones and under physiological conditions localizes
mainly in the endoplasmic reticulum.27,28 A growing body of
evidence suggests that GRP78/BiP has a key role in the unfolded
protein response via transport of proteins across the endoplasmic reticulum membrane that are involved in regulation
of tumor progression, proliferation, angiogenesis, autophagy and
apoptosis.12,13,29,30 There is increasing evidence that GRP78/BiP
overexpression is associated with resistance to therapeutic agents
in several tumor types.31 Importantly, GRP78/BiP relocation to the
cell membrane in response to endoplasmic reticulum stress has
been associated with cell transformation and development of
drug resistance.32,33 Thus, the discovery of this radiation-inducible
antigen clearly suggests that the cellular responses to XRT can be
explored for retargeting of Ad-mediated therapeutic gene delivery
to tumors.
In this study, we evaluated the utility of employing a peptide
recognizing an XRT-induced neoantigen for targeting of Admediated gene delivery. To develop XRT-targeted recombinant
Ad5-based vectors, we genetically incorporated the GIRLRG
peptide that binds speciﬁcally to GRP78/BiP into the C-terminus
of de-knobbed ﬁber-ﬁbritin chimera protein comprising the entire
Ad5 ﬁber shaft fused to the foldon of bacteriophage T4 ﬁbritin.
Initial evaluation of recombinant Ad vectors demonstrated that
genetic incorporation of ﬁber-ﬁbritin-GRP78-binding peptide
resulted in expression of trimeric fusion protein molecules on
the surface of Ad particles. We found that targeting peptides
employed in this study did not disrupt the trimerization capability

of the Ad ﬁber, and antigen recognition of the GRP78-binding
peptide was retained. In addition, we demonstrated the ability of
the GIRLRG peptide fused to ﬁber-ﬁbritin chimera to provide
speciﬁc and efﬁcient targeting of irradiated cancer cells for
Ad-mediated gene transfer.
Although biodistribution study revealed that the absolute levels
of reporter gene expression following injection of Ad5Luc with
wild-type ﬁber in the human D54MG tumor remain higher in
comparison with ﬁber-modiﬁed Ad vector, the utilization of the
GRP78-binding peptide in Ad ﬁber rather than the wild-type Ad5
ﬁber produced a signiﬁcant increase in reporter gene expression
in the irradiated xenografts in comparison with the mock-treated
tumors. In addition, GRP78-targeted Ad vectors provide an
additional level of tumor speciﬁcity via circumvention of CAR
deﬁciency of low-CAR/high-GRP78 cancer cells and abolishment of
Ad transduction to high-CAR-expressing normal cells. However,
the performance of radiation-guided Ad used in this study has
been suboptimal because of high basal levels of GRP78 expression
in un-irradiated glioma cells. As only a subset of patients may have
tumors that are efﬁciently infected by Ads with wild-type ﬁber
upon intralesional injection, the utilization of radiation-guided
Ad vectors, including conditionally replicative oncolytic Ads, by
expression of XRT-induced neoantigen targeting ligands in the
ﬁber may prove extremely useful in producing maximum beneﬁt
from combination of XRT and Ad-based gene therapy.
Thus, low-dose irradiation of tumor tissue can be harnessed
to improve binding and transfer of ﬁber-modiﬁed Ad vectors to
XRT-induced neoantigens in tumor tissue and subsequently
produce therapeutic gene expression. The combination of gene
therapy and XRT could improve the outcome of cancer treatment.
A broad range of different gene therapy approaches, including
cytolytic and corrective gene therapy, have been successfully
applied for experimental therapy in combination with XRT in
animal models, with translation into early clinical trials.34 This
would provide the possibility of utilizing multiple targeting
approaches for combined gene therapy and XRT modalities.
Gene therapy strategies offer the potential for speciﬁc targeting
at several levels, including transcriptional and transductional
targeting. Transcriptional targeting is based on employment of
both cis-acting and trans-acting elements. The cis-acting components include promoters as well as enhancer regions that also
regulate expression of a particular gene. The trans-acting elements
belong to a growing group of transcription factors that bind to
speciﬁc sites within the promoter and/or enhancer regions.
On this basis, a number of groups, including ours, demonstrated
that expression of radiation-inducible genes such as cytokines and
growth factors (for example, early growth factor-1)35 as well as
immediate-early genes encoding transcription factors (for example, Fos, Jun, AP-, and NF-κB) is variable and cell dependent.36,37
Activated immediate-early genes interact with the promoter
region of the so-called late-responding genes, coding for cytokines, involved in the inﬂammation process (for example, IL-6),
and growth factors, involved in cell survival (for example, TGFβ1,
TNF-α).38–40 Thus, the promoters from many stress response genes
related to cellular fate following DNA damage are potential
candidates for cancer gene therapy. At present, several radiationinducible promoters including Egr-1,41–43 tPA,44 p21/WAF-145 and
GADD45α46,47 were used for gene delivery in combination with
radiation therapy strategies.
Results of in vitro and animal studies demonstrated that
transductional control of gene expression using the genetically
incorporated GIRLRG peptide that is responsive to ionizing radiation provides an attractive approach for combination radiation
therapy and gene therapy against the radiation/chemoresistant
subset of GRP78-overexpressed tumor cells. In addition, the search
for methods to introduce genes into malignant brain tumor cells
led to many advances in the development of cytoreductive gene
therapy strategies such as oncolytic virotherapy.48 Virotherapy
Cancer Gene Therapy (2016), 303 – 314
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Figure 4. Adenoviral vector targeting XRT-induced neoantigens—in vivo analysis. (a) Human glioma D54MG cells were injected into the left
and right ﬂanks of athymic nude mice. D54MG tumor xenografts in both hind limbs were irradiated three times at 3 Gy over 24 h (right) or at
0 Gy (left). Optical images were acquired at different time points after injection into the tumor site with 1 × 1010 vp of AdGRP78-BPeGFP. (b) To
evaluate the levels of eGFP expression, D54MG tumors in the right hind limbs were irradiated three times at 3 Gy and the left hind limbs
were untreated; the mice were then injected with 1 × 1010 vp per tumor of AdGRP78-BPeGFP vector. Optical images were acquired, and
background-adjusted ﬂuorescence was assessed for each irradiated (ﬁlled circle symbol) or untreated (open square symbol) tumor at different
time points after Ad injection. (c) The irradiated-to-mock-irradiated (XRT/mock) ratios of ﬂuorescence intensity were calculated for each
individual animal. (d) To evaluate Luc expression 5 × 106 of D54MG cells were s.c. injected into both the left and the right ﬂanks of athymic
nude mice. Eleven days after cell injection, tumors in the left hind limbs were irradiated three times at 3 Gy and the right hind limbs
were untreated. Mice were randomly divided into groups receiving 1 × 1010 vp per tumor of AdGRP78-BPLuc or Ad5Luc. Three days after Ad
injection the animals were sacriﬁced, tumors were harvested and snap-frozen in ethanol/dry ice mix, and Luc reporter gene expression was
assessed for each animal. Each point represents the RLU per mg total protein for each irradiated (ﬁlled circle symbol) or untreated (open
square symbol) tumor tissue lysate. (e) The irradiated-to-mock-irradiated (XRT/mock) ratios were calculated for each individual animal with the
RLU normalized by the protein concentration of the tumor tissue lysate. The XRT/mock ratios were signiﬁcantly increased in mice following
i.t. injection with ﬁber-modiﬁed AdGRP78-BPLuc in comparison with Ad5Luc-expressing wild-type ﬁber. Ad, adenovirus; eGFP, enhanced
green ﬂuorescent protein; GFP, green ﬂuorescent protein; GRP78, glucose-regulated protein 78; Luc, luciferase; RLU, relative light units;
s.c., subcutaneously; VP, viral particles; XRT, radiotherapy.

represents a powerful means of achieving targeted anti-glioma
therapy, which has been rapidly translated into human clinical
trials.49 Of note, a range of virotherapy agents have been
employed for anti-cancer treatment in combination with XRT.50
In this regard, the ability to engineer conditionally replicating Ad
to infect and replicate preferentially in tumor cells overexpressing
XRT-induced neoantigens constitutes the key facet of their design
allowing targeted action. It is hypothesized that the combination
Cancer Gene Therapy (2016), 303 – 314

of transcriptional and transductional targeting strategies will
operate in functional synergy to provide higher levels of tumor
selectivity of oncolytic virotherapy agents.
In conclusion, we have developed a panel of ﬁber-modiﬁed Ads
containing a gene encoding the GRP78-binding peptide inserted
into the C-terminus of the ﬁber-ﬁbritin knobless fusion protein.
We have explored the utility of employing a transductional
targeting approach for radiation-guided Ad gene transfer. We
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have evaluated reporter gene expression of ﬁber-modiﬁed Ad
vectors in vitro and the use of a s.c. human glioma xenograft
tumor model. Our results demonstrate that infection with ﬁbermodiﬁed Ads resulted in increased gene transfer following XRT in
comparison with mock-treated tumors. The results of preliminary
studies using radiation-guided Ads in combination with XRT
provide a novel strategy to link XRT and gene therapy for glioma.
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